| Literature DB >> 29900517 |
Clarissa Rocha Dos Santos1, Richard da Rocha Filgueiras2, Patrícia Furtado Malard3, Andre Rodrigues da Cunha Barreto-Vianna4, Kaique Nogueira1, Carolina da Silva Leite1, Eduardo Maurício Mendes de Lima5.
Abstract
BACKGROUND: The cranial cruciate ligament rupture (CCLR) is the most commonly encountered orthopedic condition in dogs. Among the various techniques to treat this condition, tibial tuberosity advancement (TTA) has been used to obtain rapid recovery of the affected knee. The objective of this study was to evaluate the viability of the use of mesenchymal stem cells (MSC) implanted in the osteotomy site obtained by TTA in nine dogs diagnosed with CCLR.Entities:
Keywords: Biotechnology; Joints; Knee; Orthopedics
Year: 2018 PMID: 29900517 PMCID: PMC5999594 DOI: 10.1186/s40634-018-0130-z
Source DB: PubMed Journal: J Exp Orthop ISSN: 2197-1153
Fig. 1Use of stem cells. Photograph in craniomedial view demonstrating percutaneous application of stem cells at the osteotomy site 8 days after the surgical procedure
Fig. 2Photomicrograph of stem cells. Photomicrography demonstrating MSC (a) and osteocytes after Von Kossa staining demonstrating the calcium (reddish coloration) (b)
Fig. 3Representative data for the expression of osteocyte mesenchymal stem cell surface markers markers from negative (a, b and c) and positive (d, e and f) controls using immunoglobulin and specific antibody for CD44, CD29 and CD90. The number of cells analyzed was 1,000,000 for each of the labeled cell types. Purchased from AMNIS employing DiVa software 4.0 and analyzed with Flowjo / Mac version 9.4.7
Fig. 4Expression of cell markers OCT3.4 (a) and SOX2 (b) in mesenchymal stem cells of osteocytes using immunoglobulin and specific antibody. The number of cells analyzed was 1,000,000 for each of the labeled cell types, Purchased from AMNIS employing DiVa software 4.0 and analyzed with Flowjo / Mac version 9.4.7
Fig. 5Radiographs showing the periods evaluated and the scores. Images a, b, c, d and e represent animals of the GT, respectively, in the periods of 15, 30, 60, 90 and 120 days. Images f, g, h, i and j represent GC animals, respectively, in the periods of 15, 30, 60, 90 and 120 days. Score II (a), Score III (b, f and G), Score IV (c, d, e, h, i and j)
Classification of ossification (%), according to Hoffman et al. 2006, of the animals from the control group (GC) and those treated with mesenchymal stem cells group (GT) throughout the evaluation period
|
| Day 15 | Day 30 | Day 60 | Day 90 | Day 120 |
| |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GC | GT | GC | GT | GC | GT | GC | GT | GC | GT | ||
| ZERO | 50 | 75 | 20 | 50 | 10 | – | – | – | – | – | < 0,0001 |
| I | 30 | 12,5 | 10 | 12,5 | 10 | 12,5 | – | – | 10 | 12,5 | 0,07 |
| II | – | 12,5 | 40 | 25 | 50 | 25 | 30 | – | 20 | – | < 0,0001 |
| III | 20 | – | 20 | 12,5 | – | 50 | 30 | 62,5 | 30 | 50 | < 0,0001 |
| IV | – | – | 10 | – | 30 | 12,5 | 40 | 37,5 | 40 | 37,5 | 0,009 |
The Chi-square test with a significance level of p ≤ 0.05 was performed between the same periods for the different groups
- Mean + standard deviation of the mean of the trabeculae density of the spongy substance (%) in the control (GC) and treated (GT) groups. The Mann-Whitney test was applied between the groups in each period
| Day 15 | day 30 | Day 60 | Day 90 | Day 120 | |
|---|---|---|---|---|---|
| GC | 39,32 ± 6,42 | 71,50 ± 4,43* | 70,99 ± 3,95 | 66,40 ± 5,51 | 66,67 ± 8,26 |
| GT | 48,81 ± 7,22 | 45,44 ± 7,34 | 64,50 ± 9,78 | 61,25 ± 4,49 | 68,45 ± 5,55 |
Asterisk (*) expressed statistical difference p ≤ 0.05 between the control group and the treated group at the same evaluation time. The absence of an asterisk means that there was no statistical difference between the two groups at the same time of evaluation